Alendronate lowers cholesterol synthesis in the central nervous system of rats - a preliminary study

L Cibickova1, R Hyspler, N Cibicek

  • 1Second Department of Medicine, University Hospital, Hradec Králové, Czech Republic. cibickova@seznam.cz

Insights

Alendronate, a bisphosphonate, significantly reduces cholesterol synthesis in the rat central nervous system (CNS). However, it does not affect plasma cholesterol levels, indicating a specific CNS impact.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Pharmacology

Background:

  • Nitrogen-containing bisphosphonates inhibit farnesyl diphosphate synthase.
  • The impact of these drugs on central nervous system (CNS) cholesterol synthesis is unknown.

Purpose of the Study:

  • To investigate the effect of alendronate on cholesterol synthesis rates in specific rat CNS regions.
  • To assess alendronate's influence on plasma cholesterol levels.

Main Methods:

  • Rats were administered alendronate or vehicle orally for 9 days.
  • Cholesterol synthesis was measured in brain regions (basal ganglia, frontal cortex, hippocampus) and spinal cord using deuterium incorporation.
  • Plasma cholesterol levels were also analyzed.

Main Results:

  • Alendronate significantly reduced cholesterol synthesis rates in the frontal cortex, hippocampus, and spinal cord (p<0.001).
  • No significant alteration in plasma cholesterol levels was observed in the alendronate-treated group.

Conclusions:

  • This study provides the first experimental evidence that alendronate inhibits cholesterol biosynthesis within the CNS.
  • Alendronate demonstrates a specific inhibitory effect on CNS cholesterol synthesis, independent of plasma cholesterol levels.

Related Concept Videos